Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
This is a phase II randomised, double-blind, dose finding, repeat dose Phase II multicentre study of ODX for the treatment of patients with castration resistant prostate cancer (CRPC) and skeletal metastases. The primary objective is to evaluate the relative change from baseline in response markers related to bone metabolism (alkaline phosphatase (B-ALP) and S P1NP) at 12 weeks of three different doses of ODX (3.0, 6.0 and 9.0 mg/kg ODX).
Epistemonikos ID: b26c81751bcc9eb47634c8de042f7c6a7ee8a569
First added on: May 17, 2024